Works matching IS 00099236 AND DT 2022 AND VI 111 AND IP 1
Results: 38
Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 77, doi. 10.1002/cpt.2480
- By:
- Publication type:
- Article
Real‐World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 21, doi. 10.1002/cpt.2479
- By:
- Publication type:
- Article
ASCPT News.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 17, doi. 10.1002/cpt.2478
- Publication type:
- Article
The "Coming of Age" of Real‐World Evidence in Drug Development and Regulation.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 11, doi. 10.1002/cpt.2465
- Publication type:
- Article
In This Issue.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 9, doi. 10.1002/cpt.2484
- Publication type:
- Article
Integration of Real‐World Data and Genetics to Support Target Identification and Validation.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 63, doi. 10.1002/cpt.2477
- By:
- Publication type:
- Article
The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 135, doi. 10.1002/cpt.2474
- By:
- Publication type:
- Article
Highlights.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 15, doi. 10.1002/cpt.2472
- Publication type:
- Article
Precision Reimbursement for Precision Medicine: Using Real‐World Evidence to Evolve From Trial‐and‐Project to Track‐and‐Pay to Learn‐and‐Predict.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 52, doi. 10.1002/cpt.2471
- By:
- Publication type:
- Article
The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 122, doi. 10.1002/cpt.2466
- By:
- Publication type:
- Article
From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 321, doi. 10.1002/cpt.2476
- By:
- Publication type:
- Article
The Use of Real‐World Data to Assess the Impact of Safety‐Related Regulatory Interventions.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 98, doi. 10.1002/cpt.2464
- Publication type:
- Article
Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 310, doi. 10.1002/cpt.2462
- By:
- Publication type:
- Article
Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 90, doi. 10.1002/cpt.2461
- By:
- Publication type:
- Article
Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 302, doi. 10.1002/cpt.2454
- By:
- Publication type:
- Article
The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 283, doi. 10.1002/cpt.2453
- By:
- Publication type:
- Article
Regulator‐Requested Non‐Interventional Postauthorization Safety and Effectiveness Studies for Oncology Drugs: A Systematic Review.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 155, doi. 10.1002/cpt.2450
- By:
- Publication type:
- Article
Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 44, doi. 10.1002/cpt.2449
- By:
- Publication type:
- Article
Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G‐CSF, in Pediatric Patients with Solid Tumors.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 293, doi. 10.1002/cpt.2433
- By:
- Publication type:
- Article
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 272, doi. 10.1002/cpt.2430
- By:
- Publication type:
- Article
TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real‐World Clinical Results.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 263, doi. 10.1002/cpt.2428
- By:
- Publication type:
- Article
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 252, doi. 10.1002/cpt.2427
- By:
- Publication type:
- Article
Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 35, doi. 10.1002/cpt.2410
- By:
- Publication type:
- Article
Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 243, doi. 10.1002/cpt.2400
- By:
- Publication type:
- Article
Assessing and Interpreting Real‐World Evidence Studies: Introductory Points for New Reviewers.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 145, doi. 10.1002/cpt.2398
- By:
- Publication type:
- Article
Comparative Safety of Dipeptidyl Peptidase‐4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population‐Based Cohort Studies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 227, doi. 10.1002/cpt.2381
- By:
- Publication type:
- Article
Calibrating Real‐World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 179, doi. 10.1002/cpt.2304
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 1, doi. 10.1002/cpt.2292
- Publication type:
- Article
When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials?
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 116, doi. 10.1002/cpt.2256
- By:
- Publication type:
- Article
Angiotensin‐Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 218, doi. 10.1002/cpt.2377
- By:
- Publication type:
- Article
When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 108, doi. 10.1002/cpt.2255
- By:
- Publication type:
- Article
Understanding Use of Real‐World Data and Real‐World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 150, doi. 10.1002/cpt.2272
- By:
- Publication type:
- Article
Prevalence of Avoidable and Bias‐Inflicting Methodological Pitfalls in Real‐World Studies of Medication Safety and Effectiveness.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 209, doi. 10.1002/cpt.2364
- By:
- Publication type:
- Article
Association of Vitamin K and Non‐Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 200, doi. 10.1002/cpt.2362
- By:
- Publication type:
- Article
Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 168, doi. 10.1002/cpt.2351
- By:
- Publication type:
- Article
Uncontrolled Extensions of Clinical Trials and the Use of External Controls—Scoping Opportunities and Methods.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 187, doi. 10.1002/cpt.2346
- By:
- Publication type:
- Article
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 30, doi. 10.1002/cpt.2253
- By:
- Publication type:
- Article
When Can We Trust Real‐World Data To Evaluate New Medical Treatments?
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 24, doi. 10.1002/cpt.2252
- By:
- Publication type:
- Article